Search - tctmd.com

Displaying 201 - 220 of 375

Sort: Relevancy | Date

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

L.A. McKeown

October 12, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

Todd Neale

August 26, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

$A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years$

News Daily News

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Yael L. Maxwell

August 10, 2018

News Daily News

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Yael L. Maxwell

August 03, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

Advertisement

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

TCTMD’s Top 10 Most Popular Stories for August 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content